Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications
International Journal of Cancer · 01.01.2027 · 160 (1) · 7-23
DOI: 10.1002/ijc.70704 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 19.08.2026. Verfasst von Min Xing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hunan University of Chinese Medicine, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, DNA Methylation, Circadian Clocks, Biomarkers, Tumor. Die Arbeit nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Hunan Provincial Natural Science Foundation, Joint Project, the Hunan University of Chinese Medicine, Intellectual Property Transformation and Application Special Fund, the Hunan Provincial Department of Science and Technology, Key R&D Program.
Abstract (Originalsprache)
Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states and evolutionary trajectories associated with therapeutic pressure. Meanwhile, the circadian rhythm system regulates multiple cancer‐related processes, including DNA damage repair, cell‐cycle progression, metabolic adaptation, and immune microenvironment remodeling, thereby influencing OC development and treatment responses. Accumulating evidence suggests the existence of a bidirectional interplay between DNAm landscapes and the circadian clock network in OC. This review summarizes the emerging mechanisms underlying the crosstalk between DNAm and circadian reprogramming in OC, and further discusses their potential applications in early detection, prognostic stratification, dynamic monitoring of platinum resistance, and chronotherapy‐based therapeutic strategies. Although current findings highlight the promising translational potential of the DNAm–circadian axis, its clinical implementation remains constrained by tumor heterogeneity, variations in sampling time points, cellular composition complexity, and insufficient validation across experimental models and clinical cohorts. Future integration of time‐resolved sampling approaches, liquid biopsy platforms, single‐cell and spatial epigenomic technologies, as well as prospective clinical trials evaluating circadian‐guided interventions, may further define the translational boundaries and clinical utility of DNAm–circadian coupling in precision diagnosis and treatment of OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan University of Chinese Medicine, Changsha, Hunan, China.
- Hinye Pharmaceutical Co. Ltd., Changsha, Hunan, China.
- The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
ORCID-Profile: Huiping Liu
Förderung
- the Hunan Provincial Natural Science Foundation, Joint Project
- the Hunan University of Chinese Medicine, Intellectual Property Transformation and Application Special Fund
- the Hunan Provincial Department of Science and Technology, Key R&D Program
- the Hunan University of Chinese Medicine, Graduate Innovation Project
- the Open Fund of the Provincial-Ministerial Co-constructed National Key Laboratory of Chinese Herbal Powder and Innovative Drugs
Zitieren
APA
Xing, M., Zhou, C., Tang, Y., Xu, S., Zhou, S., Liu, W., & Liu, H. (2027). Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications. International Journal of Cancer, 160(1), 7-23. https://doi.org/10.1002/ijc.70704
Vancouver
Xing M, Zhou C, Tang Y, Xu S, Zhou S, Liu W, et al. Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications. International Journal of Cancer. 2027;160(1):7-23. doi:10.1002/ijc.70704
BibTeX
@article{Xing2027,
author = {Xing, Min and Zhou, Chang and Tang, Yi and Xu, Shuhui and Zhou, Shasha and Liu, Weiai and Liu, Huiping},
title = {Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications},
journal = {International Journal of Cancer},
year = {2027},
volume = {160},
number = {1},
pages = {7--23},
doi = {10.1002/ijc.70704}
}
EUVIMED